Literature DB >> 11120991

The ovine cathelicidin SMAP29 kills ovine respiratory pathogens in vitro and in an ovine model of pulmonary infection.

K A Brogden1, V C Kalfa, M R Ackermann, D E Palmquist, P B McCray, B F Tack.   

Abstract

Cathelicidins are antimicrobial peptides from sheep (SMAP29 and SMAP34), rabbits (CAP11 and CAP18), rodents (CRAMP), and humans (FALL39, LL37, and h/CAP18). In a broth microdilution assay against nine ovine pathogens, SMAP29, SMAP34, mouse CRAMP, CAP18, CAP18(31), CAP18(28), CAP18(22), and CAP18(21a) were the most active, with MICs as low as 0.6 microg/ml. Other cathelicidins were less active. In lambs with pneumonia, 0.5 mg of SMAP29 reduced the concentration of bacteria in both bronchoalveolar lavage fluid and consolidated pulmonary tissues. Hence, the antimicrobial activity of SMAP29 suggests that it has applications in the treatment of respiratory tract infections.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11120991      PMCID： PMC90286          DOI： 10.1128/AAC.45.1.331-334.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  The lactoperoxidase system functions in bacterial clearance of airways.

Authors:  C Gerson; J Sabater; M Scuri; A Torbati; R Coffey; J W Abraham; I Lauredo; R Forteza; A Wanner; M Salathe; W M Abraham; G E Conner
Journal:  Am J Respir Cell Mol Biol       Date:  2000-06       Impact factor: 6.914

2.  Visual assessment of pneumonic area in ovine lungs.

Authors:  G Valero; M R Alley; B W Manktelow
Journal:  N Z Vet J       Date:  1992-06       Impact factor: 1.628

3.  Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane.

Authors:  M Wu; R E Hancock
Journal:  J Biol Chem       Date:  1999-01-01       Impact factor: 5.157

4.  Genetic and physical mapping of the ovine cystic fibrosis gene.

Authors:  S J Tebbutt; M F Broom; T C van Stijn; G W Montgomery; D F Hill
Journal:  Cytogenet Cell Genet       Date:  1996

5.  A large animal model of pseudomonas pneumonia.

Authors:  G A Patterson; T R Todd
Journal:  J Surg Res       Date:  1982-09       Impact factor: 2.192

Review 6.  Towards an ovine model of cystic fibrosis.

Authors:  A Harris
Journal:  Hum Mol Genet       Date:  1997-12       Impact factor: 6.150

7.  Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.

Authors:  J Turner; Y Cho; N N Dinh; A J Waring; R I Lehrer
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

8.  Pasteurella haemolytica lipopolysaccharide-associated protein induces pulmonary inflammation after bronchoscopic deposition in calves and sheep.

Authors:  K A Brogden; M R Ackermann; B M Debey
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  An ovine CFTR variant as a putative cystic fibrosis causing mutation.

Authors:  S J Tebbutt; A Harris; D F Hill
Journal:  J Med Genet       Date:  1996-07       Impact factor: 6.318

10.  Pseudomonas aeruginosa-induced lung and pleural injury in sheep. Differential protective effect of circulating versus alveolar immunoglobulin G antibody.

Authors:  J F Pittet; M A Matthay; G Pier; M Grady; J P Wiener-Kronish
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808
View more
  33 in total

1.  Congeners of SMAP29 kill ovine pathogens and induce ultrastructural damage in bacterial cells.

Authors:  V C Kalfa; H P Jia; R A Kunkle; P B McCray; B F Tack; K A Brogden
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  Antimicrobial activity and bacterial-membrane interaction of ovine-derived cathelicidins.

Authors:  Rachel C Anderson; Robert E W Hancock; Pak-Lam Yu
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

Review 3.  Endogenous production of antimicrobial peptides in innate immunity and human disease.

Authors:  Richard L Gallo; Victor Nizet
Journal:  Curr Allergy Asthma Rep       Date:  2003-09       Impact factor: 4.806

4.  A member of the cathelicidin family of antimicrobial peptides is produced in the upper airway of the chinchilla and its mRNA expression is altered by common viral and bacterial co-pathogens of otitis media.

Authors:  Glen McGillivary; William C Ray; Charles L Bevins; Robert S Munson; Lauren O Bakaletz
Journal:  Mol Immunol       Date:  2006-11-20       Impact factor: 4.407

5.  Cathelicidin administration protects mice from Bacillus anthracis spore challenge.

Authors:  Mark W Lisanby; Melissa K Swiecki; Brian L P Dizon; Kathryn J Pflughoeft; Theresa M Koehler; John F Kearney
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

Review 6.  Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?

Authors:  Nicole K Brogden; Kim A Brogden
Journal:  Int J Antimicrob Agents       Date:  2011-07-05       Impact factor: 5.283

7.  Activity of cathelicidin peptides against Chlamydia spp.

Authors:  Manuela Donati; Korinne Di Leo; Monica Benincasa; Francesca Cavrini; Silvia Accardo; Alessandra Moroni; Renato Gennaro; Roberto Cevenini
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

8.  Pegylation of antimicrobial peptides maintains the active peptide conformation, model membrane interactions, and antimicrobial activity while improving lung tissue biocompatibility following airway delivery.

Authors:  Christopher J Morris; Konrad Beck; Marc A Fox; David Ulaeto; Graeme C Clark; Mark Gumbleton
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

9.  Gene profiling studies in the neonatal ovine lung show enhancing effects of VEGF on the immune response.

Authors:  Fatoumata B Sow; Jack M Gallup; David K Meyerholz; Mark R Ackermann
Journal:  Dev Comp Immunol       Date:  2009-02-02       Impact factor: 3.636

10.  Killing of trypanosomatid parasites by a modified bovine host defense peptide, BMAP-18.

Authors:  Lee R Haines; Jamie M Thomas; Angela M Jackson; Brett A Eyford; Morteza Razavi; Cristalle N Watson; Brent Gowen; Robert E W Hancock; Terry W Pearson
Journal:  PLoS Negl Trop Dis       Date:  2009-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.